Stonepine Capital Management, LLC Enanta Pharmaceuticals Inc Transaction History

Stonepine Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$38.13 - $76.93 $4.57 Million - $9.23 Million	-119,972 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$56.06 - $74.11 $6.73 Million - $8.89 Million	119,972 New	119,972 $8.54 Million
Q4 2019 Feb 13, 2020	SELL	$57.95 - $66.61 $7.53 Million - $8.65 Million	-129,867 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$60.08 - $88.17 $3.87 Million - $5.68 Million	64,383 Added 98.32%	129,867 $7.8 Million
Q2 2019 Aug 13, 2019	BUY	$81.3 - $97.35 $377,557 - $452,093	4,644 Added 7.63%	65,484 $5.53 Million
Q1 2019 May 14, 2019	BUY	$69.08 - $105.66 $4.2 Million - $6.43 Million	60,840 New	60,840 $5.81 Million
Q1 2018 May 14, 2018	SELL	$57.91 - $92.15 $12.6 Million - $20.1 Million	-218,434 Closed	0 $0
Q4 2017 Feb 13, 2018	SELL	$45.65 - $59.37 $7.83 Million - $10.2 Million	-171,566 Reduced 43.99%	218,434 $12.8 Million
Q3 2017 Nov 13, 2017	SELL	$37.91 - $46.8 $3.88 Million - $4.79 Million	-102,265 Reduced 20.77%	390,000 $18.3 Million
Q2 2017 Aug 14, 2017	BUY	N/A	492,265	492,265 $17.7 Million

110

21.1M

4.8K

4.6K

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $198M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

Get notified when there are updates to the investment portfolio of Stonepine Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Stonepine Capital Management, LLC with notifications on news.